Folate, homocysteine, endothelial function and cardiovascular disease

Journal of Nutritional Biochemistry

Volumn 15, Issue 2, 2004, Pages 64-79

  Moat, Stuart J ^a   Lang, Derek ^a   McDowell, Ian F W ^a   Clarke, Zoe L ^a   Madhavan, Anil K ^a   Lewis, Malcolm J ^a   Goodfellow, Jonathan ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cardiovascular disease (CVD); Endothelial function; Flow mediated dilatation (FMD); Folate; Homocysteine; Nitric oxide (NO)

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETAINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBO; PYRIDOXINE; SCAVENGER; SUPEROXIDE; TETRAHYDROBIOPTERIN;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM LESION; ENZYME DEFECT; EPIDEMIOLOGICAL DATA; FAMILIAL HYPERCHOLESTEROLEMIA; FOLATE METABOLISM; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; IN VITRO STUDY; LIPID PEROXIDATION; META ANALYSIS; NEUROLOGIC DISEASE; OXIDATIVE STRESS; PLEIOTROPY; PROPHYLAXIS; REVIEW; RISK FACTOR; SAFETY; SIDE EFFECT; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULARIZATION; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

EID: 1242306238     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2003.08.010     Document Type: Review

References (102)

1. Hoffbrand A.V., Weir D.G. The history of folic acid. Br J Haematol. 113:2001;579-589.
2. Olney R.S., Mulinare J. Trends in neural tube defect prevalence, folic acid fortification, and vitamin supplement use. Semin Perinatol. 26:2002;277-285.
3. Morris M.S. Folate, homocysteine, and neurological function. Nutr Clin Care. 5:2002;124-132.
4. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia a review . J Nutr. 132:2002;2350-2355.
5. Scott J.M., Weir D.G. Folic acid, homocysteine and one-carbon metabolism a review of the essential biochemistry . J Cardiovasc Risk. 5:1998;223-227.
6. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 19:1999;217-246.
7. Finkelstein J.D. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost. 26:2000;219-225.
8. Mudd S.H., Levy H.L., Skovby F. Disorders of transsulfuration. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular basis of inherited disease. 7th ed. 1995;1279-1327 McGraw-Hill, New York.
9. Moat S.J., Bonham J.R., Tanner M.S., Allen J.C., Powers H.J. Recommended approaches for the laboratory measurement of homocysteine in the diagnosis and monitoring of patients with hyperhomocysteinaemia. Ann Clin Biochem. 36:1999;372-379.
10. McCully K.S. Vascular pathology of homocysteinemia implications for the pathogenesis of arteriosclerosis . Am J Pathol. 56:1969;111-128.
11. Mudd S.H., Havlik R., Levy H.L., McKusick V.A., Feinleib M. Cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet. 34:1982;1018-1021.
12. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., Den Heijer M., Kluijtmans L.A., van den Heuvel L.P. A candidate genetic risk factor for vascular disease a common mutation in methylenetetrahydrofolate reductase . Nat Genet. 10:1995;111-113.
13. Brattström L., Wilcken D.E., Ohrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease the result of a metaanalysis . Circulation. 98:1998;2520-2526.
14. Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., Schouten E.G. MTHFR 677C->T polymorphism and risk of coronary heart disease a meta- analysis . JAMA. 288:2002;2023-2031.
15. Demuth K., Moatti N., Hanon O., Benoit M.O., Safar M., Girerd X. Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry. Arterioscler Thromb Vasc Biol. 18:1998;1838-1843.
16. Butler R., Morris A.D., Struthers A.D. The T allele of the C677T, 5, 10-methylenetetrahydrofolate reducatse (MTHFR) gene polymorphism may protect endothelial function in young, normal subjects. Arterioscler Thromb Vasc Biol. 22:2002;193-194.
17. Hustad S., Ueland P.M., Vollset S.E., Zhang Y., Bjorke-Monsen A.L., Schneede J. Riboflavin as a determinant of plasma total homocysteine effect modification by the methylenetetrahydrofolate reductase C677T polymorphism . Clin Chem. 46:2000;1065-1071.
18. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
19. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattstrom L.E., Ueland P.M., Palma-Reis R.J., Boers G.H., Sheahan R.G., Israelsson B., Uiterwaal C.S., Meleady R., McMaster D., Verhoef P., Witteman J., Rubba P., Bellet H., Wautrecht J.C., de Valk H.W., Sales Luis A.C., Parrot-Rouland F.M., Tan K.S., Higgins I., Garcon D., Andria G. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 277:1997;1775-1781.
20. Danesh J., Lewington S. Plasma homocysteine and coronary heart disease systematic review of published epidemiological studies . J Cardiovasc Risk. 5:1998;229-232.
21. Evans R.W., Shaten B.J., Hempel J.D., Cutler J.A., Kuller L.H. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 17:1997;1947-1953.
22. Alfthan G., Pekkanen J., Jauhiainen M., Pitkaniemi J., Karvonen M., Tuomilehto J., Salonen J.T., Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:1994;9-19.
23. Clarke R., Lewington S., Donald A., Johnston C., Refsum H., Stratton I., Jacques P., Breteler M.M., Holman R. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk. 8:2001;363-369.
24. Magni E., Bianchetti A., Rozzini R., Trabucchi M. Influence of nutritional intake on 6-year mortality in an Italian elderly population. J Nutr Elder. 13:1994;25-34.
25. Ness A.R., Powles J.W. The role of diet, fruit and vegetables and antioxidants in the aetiology of stroke. J Cardiovasc Risk. 6:1999;229-234.
26. Verhoef P., Stampfer M.J., Buring J.E., Gaziano J.M., Allen R.H., Stabler S.P., Reynolds R.D., Kok F.J., Hennekens C.H., Willett W.C. Homocysteine metabolism and risk of myocardial infarction relation with vitamins B6, B12, and folate . Am J Epidemiol. 143:1996;845-859.
27. Selhub J., Jacques P.F., Bostom A.G., D'Agostino R.B., Wilson P.W., Belanger A.J., O'Leary D.H., Wolf P.A., Schaefer E.J., Rosenberg I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 332:1995;286-291.
28. Robinson K., Arheart K., Refsum H., Brattstrom L., Boers G., Ueland P., Rubba P., Palma-Reis R., Meleady R., Daly L., Witteman J., Graham I. Low circulating folate and vitamin B6 concentrations risk factors for stroke, peripheral vascular disease and coronary artery disease. European COMAC Group . Circulation. 97:1998;437-443.
29. Silberberg J.S., Crooks R.L., Wlodarczyk J.H., Fryer J.L. Association between plasma folate and coronary disease independent of homocysteine. Am J Cardiol. 87:2001;1003-1004.
30. Quere I., Perneger T.V., Zittoun J., Bellet H., Gris J.C., Daures J.P., Schved J.F., Mercier E., Laroche J.P., Dauzat M., Bounameaux H., Janbon C., de Moerloose P. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism a matched case-control study . Lancet. 359:2002;747-752.
31. Pancharuniti N., Lewis C.A., Sauberlich H.E., Perkins L.L., Go R.C., Alvarez J.O., Macaluso M., Acton R.T., Copeland R.B., Cousins A.L. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 59:1994;940-948.
32. Dalery K., Lussier-Cacan S., Selhub J., Davignon J., Latour Y., Genest J. Homocysteine and coronary artery disease in French Canadian subjects relation with vitamins B12, B6, pyridoxal phosphate, and folate . Am J Cardiol. 75:1995;1107-1111.
33. Robinson K., Mayer E.L., Miller D.P., Green R., van Lente F., Gupta A., Kottke-Marchant K., Savon S.R., Selhub J., Nissen S.E., Kutner M., Topol E.J., Jacobsen D.W. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation. 92:1995;2825-2830.
34. Loehrer F.M., Angst C.P., Haefeli W.E., Jordan P.P., Ritz R., Fowler B. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol. 16:1996;727-733.
35. Schwartz S.M., Siscovick D.S., Malinow M.R., Rosendaal F.R., Beverly R.K., Hess D.L., Psaty B.M., Longstreth W.T., Koepsell T.D., Raghunathan T.E., Reitsma P.H. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 96:1997;412-417.
36. Verhoef P., Kok F.J., Kruyssen D.A., Schouten E.G., Witteman J.C., Grobbee D.E., Ueland P.M., Refsum H. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 17:1997;989-995.
37. Christensen B., Landaas S., Stensvold I., Djurovic S., Retterstol L., Ringstad J., Berg K., Thelle D.S. Whole blood folate, homocysteine in serum, and risk of first acute myocardial infarction. Atherosclerosis. 147:1999;317-326.
38. Bunout D., Petermann M., Hirsch S., de la Mazo P., Suazo M., Barrera G., Kauffman R. Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. Nutrition. 16:2000;434-438.
39. Morrison H.I., Schaubel D., Desmeules M., Wigle D.T. Serum folate and risk of fatal coronary heart disease. JAMA. 275:1996;1893-1896.
40. Rimm E.B., Willett W.C., Hu F.B., Sampson L., Colditz G.A., Manson J.E., Hennekens C., Stampfer M.J. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 279:1998;359-364.
41. Giles W.H., Kittner S.J., Croft J.B., Anda R.F., Casper M.L., Ford E.S. Serum folate and risk for coronary heart disease results from a cohort of US adults . Ann Epidemiol. 8:1998;490-496.
42. Chasan-Taber L., Selhub J., Rosenberg I.H., Malinow M.R., Terry P., Tishler P.V., Willett W., Hennekens C.H., Stampfer M.J. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 15:1996;136-143.
43. Folsom A.R., Nieto F.J., McGovern P.G., Tsai M.Y., Malinow M.R., Eckfeldt J.H., Hess D.L., Davis C.E. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins the Atherosclerosis Risk in Communities (ARIC) study . Circulation. 98:1998;204-210.
44. Giles W.H., Kittner S.J., Anda R.F., Croft J.B., Casper M.L. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke. 26:1995;1166-1170.
45. Ford E.S., Byers T.E., Giles W.H. Serum folate and chronic disease risk findings from a cohort of United States adults . Int J Epidemiol. 27:1998;592-598.
46. Voutilainen S., Lakka T.A., Porkkala-Sarataho E., Rissanen T., Kaplan G.A., Salonen J.T. Low serum folate concentrations are associated with an excess incidence of acute coronary events the Kuopio Ischaemic Heart Disease Risk Factor Study . Eur J Clin Nutr. 54:2000;424-428.
47. Loria C.M., Ingram D.D., Feldman J.J., Wright J.D., Madans J.H. Serum folate and cardiovascular disease mortality among US men and women. Arch Intern Med. 160:2000;3258-3262.
48. Voutilainen S., Rissanen T.H., Virtanen J., Lakka T.A., Salonen T. Low dietary folate intake is associated with an excess incidence of acute coronary events The Kuopio Ischemic Heart Disease Risk Factor Study . Circulation. 103:2001;2674-2680.
49. Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 101:2000;1899-1906.
50. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes D.A., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 101:2000;948-954.
51. Bellamy M.F., McDowell I.F., Ramsey M.W., Brownlee M., Newcombe R.G., Lewis M.J. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest. 29:1999;659-662.
52. Woo K.S., Chook P., Lolin Y.I., Sanderson J.E., Metreweli C., Celermajer D.S. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol. 34:1999;2002-2006.
53. van den Berg M., Boers G.H., Franken D.G., Blom H.J., Van Kamp G.J., Jakobs C., Rauwerda J.A., Kluft C., Stehouwer C.D. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 25:1995;176-181.
54. Usui M., Matsuoka H., Miyazaki H., Ueda S., Okuda S., Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia restoration by folic acid . Clin Sci (Lond). 96:1999;235-239.
55. Chao C.L., Chien K.L., Lee Y.T. Effect of short-term vitamin (folic acid, vitamins B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia. Am J Cardiol. 84:1999;1359-1361.
56. Gori T., Burstein J.M., Ahmed S., Miner S.E., Al Hesayen A., Kelly S., Parker J.D. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance a human in vivo study . Circulation. 104:2001;1119-1123.
57. Wilmink H.W., Stroes E.S., Erkelens W.D., Gerritsen W.B., Wever R., Banga J.D., Rabelink T.J. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol. 20:2000;185-188.
58. van Guldener C., Janssen M.J., Lambert J., ter Wee P.M., Donker A.J., Stehouwer C.D. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients no change in endothelial function after long-term therapy . Perit Dial Int. 18:1998;282-289.
59. Thambyrajah J., Landray M.J., McGlynn F.J., Jones H.J., Wheeler D.C., Townend J.N. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation. 102:2000;871-875.
60. Pullin C.H., Bonham J.R., McDowell I.F., Lee P.J., Powers H.J., Wilson J.F., Lewis M.J., Moat S.J. Vitamin C therapy ameliorates vascular endothelial dysfunction in treated patients with homocystinuria. J Inherit Metab Dis. 25:2002;107-118.
61. Peterson J.C., Spence J.D. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet. 351:1998;263.
62. Doshi S.N., McDowell I.F., Moat S.J., Lang D., Newcombe R.G., Kredan M.B., Lewis M.J., Goodfellow J. Folate improves endothelial function in coronary artery disease an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol. 21:2001;1196-1202.
63. Title L.M., Cummings P.M., Giddens K., Genest J.J., Nassar B.A. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol. 36:2000;758-765.
64. Chambers J.C., Ueland P.M., Obeid O.A., Wrigley J., Refsum H., Kooner J.S. Improved vascular endothelial function after oral B vitamins An effect mediated through reduced concentrations of free plasma homocysteine . Circulation. 102:2000;2479-2483.
65. Doshi S.N., McDowell I.F., Moat S.J., Payne N., Durrant H.J., Lewis M.J., Goodfellow J. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation. 105:2002;22-26.
66. Verhaar M.C., Wever R.M., Kastelein J.J., van Dam T., Koomans H.A., Rabelink T.J. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 97:1998;237-241.
67. Verhaar M.C., Wever R.M., Kastelein J.J., van Loon D., Milstien S., Koomans H.A., Rabelink T.J. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation. 100:1999;335-338.
68. Constans J., Blann A.D., Resplandy F., Parrot F., Renard M., Seigneur M., Guerin V., Boisseau M., Conri C. Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction. Br J Haematol. 107:1999;776-778.
69. Vermeulen E.G., Stehouwer C.D., Twisk J.W., van den B.M., de Jong S.C., Mackaay A.J., van Campen C.M., Visser F.C., Jakobs C.A., Bulterjis E.J., Rauwerda J.A. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis a randomised, placebo-controlled trial . Lancet. 355:2000;517-522.
70. Pullin C.H., Ashfield-Watt P.A., Burr M.L., Clark Z.E., Lewis M.J., Moat S.J., Newcombe R.G., Powers H.J., Whiting J.M., McDowell I.F. Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype. J Am Coll Cardiol. 38:2001;1799-1805.
71. van Dijk R.A., Rauwerda J.A., Steyn M., Twisk J.W., Stehouwer C.D. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness a 2-year, randomized, placebo-controlled trial . Arterioscler Thromb Vasc Biol. 21:2001;2072-2079.
72. Schnyder G., Roffi M., Pin R., Flammer Y., Lange H., Eberli F.R., Meier B., Turi Z.G., Hess O.M. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 345:2001;1593-1600.
73. Mudd S.H., Skovby F., Levy H.L., Pettigrew K.D., Wilcken B., Pyeritz R.E., Andria G., Boers G.H., Bromberg I.L., Cerone R., et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 37:1985;1-31.
74. Yap S., Boers G.H., Wilcken B., Wilcken D.E., Brenton D.P., Lee P.J., Walter J.H., Howard P.M., Naughten E.R. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically a multicenter observational study . Arterioscler Thromb Vasc Biol. 21:2001;2080-2085.
75. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998;316:894-8.
76. Den Heijer M., Brouwer I.A., Bos G.M., Blom H.J., van der Put N.M., Spaans A.P., Rosendaal F.R., Thomas C.M., Haak H.L., Wijermans P.W., Gerrits W.B. Vitamin supplementation reduces blood homocysteine levels a controlled trial in patients with venous thrombosis and healthy volunteers . Arterioscler Thromb Vasc Biol. 18:1998;356-361.
77. Lobo A., Naso A., Arheart K., Kruger W.D., Abou-Ghazala T., Alsous F., Nahlawi M., Gupta A., Moustapha A., van Lente F., Jacobsen D.W., Robinson K. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol. 83:1999;821-825.
78. van der Griend R., Biesma D.H., Haas F.J., Faber J.A., Duran M., Meuwissen O.J., Banga J.D. The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations. J Intern Med. 248:2000;223-229.
79. Wald D.S., Bishop L., Wald N.J., Law M., Hennessy E., Weir D., McPartlin J., Scott J. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med. 161:2001;695-700.
80. Jacques P.F., Selhub J., Bostom A.G., Wilson P.W., Rosenberg I.H. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 340:1999;1449-1454.
81. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases the role of oxidant stress . Circ Res. 87:2000;840-844.
82. Ellis G.R., Anderson R.A., Lang D., Blackman D.J., Morris R.H., Morris-Thurgood J., McDowell I.F., Jackson S.K., Lewis M.J., Frenneaux M.P. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure effects of short- and long-term vitamin C therapy . J Am Coll Cardiol. 36:2000;1474-1482.
83. Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 97:1996;22-28.
84. Ting H.H., Timimi F.K., Haley E.A., Roddy M.A., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation. 95:1997;2617-2622.
85. Chambers J.C., McGregor A., Jean-Marie J., Obeid O.A., Kooner J.S. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia an effect reversible with vitamin C therapy . Circulation. 99:1999;1156-1160.
86. Joshi R., Adhikari S., Patro B.S., Chattopadhyay S., Mukherjee T. Free radical scavenging behavior of folic acid evidence for possible antioxidant activity . Free Radic Biol Med. 30:2001;1390-1399.
87. Nakano E., Higgins J.A., Powers H.J. Folate protects against oxidative modification of human LDL. Br J Nutr. 86:2001;637-639.
88. Kelly P., McPartlin J., Scott J. A combined high-performance liquid chromatographic -microbiological assay for serum folic acid. Anal Biochem. 238:1996;179-183.
89. Stroes E.S., van Faassen E.E., Yo M., Martasek P., Boer P., Govers R., Rabelink T.J. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res. 86:2000;1129-1134.
90. Doshi S.N., Naka K.K., Payne N., Jones C.J., Ashton M., Lewis M.J., Goodfellow J. Flow-mediated dilatation following wrist and upper arm occlusion in humans the contribution of nitric oxide . Clin Sci (Lond). 101:2001;629-635.
91. Vasquez-Vivar J., Martasek P., Whitsett J., Joseph J., Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase an EPR spin trapping study . Biochem J. 362:2002;733-739.
92. Stroes E., Kastelein J., Cosentino F., Erkelens W., Wever R., Koomans H., Luscher T., Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 99:1997;41-46.
93. Maier W., Cosentino F., Lutolf R.B., Fleisch M., Seiler C., Hess O.M., Meier B., Luscher T.F. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol. 35:2000;173-178.
94. Shinozaki K., Hirayama A., Nishio Y., Yoshida Y., Ohtani T., Okamura T., Masada M., Kikkawa R., Kodama K., Kashiwagi A. Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol. 38:2001;1821-1828.
95. Hyndman M.E., Verma S., Rosenfeld R.J., Anderson T.J., Parsons H.G. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol. 282:2002;2167-2172.
96. Heller R., Unbehaun A., Schellenberg B., Mayer B., Werner-Felmayer G., Werner E.R. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem. 276:2001;40-47.
97. Clarke R., Armitage J. Vitamin supplements and cardiovascular risk review of the randomized trials of homocysteine-lowering vitamin supplements . Semin Thromb Hemost. 26:2000;341-348.
98. Doshi S.N., Moat S.J., McDowell I.F., Lewis M.J., Goodfellow J. Lowering plasma homocysteine with folic acid in cardiovascular disease what will the trials tell us? Atherosclerosis. 165:2002;1-3.
99. Baker F., Picton D., Blackwood S., Hunt J., Erskine M., Dyas M., Ashby M., Siva A., Brown M.J. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial. Circulation. 106:(Supplement 1):2002;741.
100. Liem A., Reynierse-Buitenwerf G.H., Zwinderman A.H., Juema J.W., van Veldhuisen D.J. Secondary prevention with folic acid Effects on clinical outcomes . Journal of the Am J Coll Cardiol. 41:2003;2105-2113.
101. Bostom A.G., Selhub J., Jacques P.F., Rosenberg I.H. Power shortage Clinical trials testing the "Homocysteine Hypothesis" against a background of folic acid-fortified cereal grain flour . Ann Intern Med. 135:2001;133-137.
102. Tucker K.L., Mahnken B., Wilson P.W., Jacques P., Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA. 276:1996;1879-1885.